PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-26.20%
Negative net income growth while GNPX stands at 63.93%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.65%
Less D&A growth vs. GNPX's 46.29%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-4.67%
Both cut yoy SBC, with GNPX at -91.09%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-515.11%
Negative yoy working capital usage while GNPX is 218.27%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.40%
Lower 'other working capital' growth vs. GNPX's 2949.26%. David Dodd would see fewer unexpected short-term demands on cash.
-12704.62%
Both negative yoy, with GNPX at -50.00%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-57.07%
Negative yoy CFO while GNPX is 52.72%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-196.22%
Negative yoy CapEx while GNPX is 72.01%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-196.22%
We reduce yoy invests while GNPX stands at 72.01%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Issuance growth of 100.00% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.